Drug Trial Radar · NCT07446998
Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
239
Actual
Start
Mar 26, 2026
Primary completion
Oct 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Veru Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the effect of enobosarm on total body weight
Conditions
- Obesity & Overweight
- Mobility Disability
- HOMA-IR
Interventions
EnobosarmDrug
Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
Semaglutide (Wegovy) weekly injectionDrug
Semaglutide for Chronic Weight Management
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.Time frame: Day 476
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
DM Clinical Research - Phoenix
Phoenix, Arizona
DM Clinical Research - MIA
Doral, Florida
Universal Axon Clinical Research (Rovia - UACR)
Doral, Florida
Paramo Health
Miami, Florida
IMIC Research a Rovia Clinical Research Company
Miami, Florida
Paramo Health
Miami, Florida
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Centennial Medical Group (CMG)
Columbia, Maryland
SKY Integrative Medical Center
Ridgeland, Mississippi
ALSA Research
New York, New York
Coastal Research Institute, LLC
Fayetteville, North Carolina
DM Clinical - Dallas
Irving, Texas
DM Clinical - Seattle
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.